NCT01613599

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Data will be collected for a maximum of 4 years from participants initiated on MabThera/Rituxan therapy by their physician according to prescribing information.

Conditions

• Granulomatosis With Polyangiitis
• Microscopic Polyangiitis

Interventions

Type	Name	Description
DRUG	Rituximab	Participants received rituximab at the discretion of their treating physicians.

Timeline

• Start date: 2012-06-20
• Primary completion: 2015-07-13
• Completion: 2017-04-28
• First posted: 2012-06-07
• Last updated: 2018-07-26
• Results posted: 2016-08-17

Locations

15 sites across 1 country: United States